UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of July 2022

Commission File Number: 001-41421

Alvotech

(Translation of registrant's name into English)

9, Rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

\boxtimes Form 20-F \square Form 40-	□ Form 40-	Form 20-F
--	------------	-----------

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Press Release

On July 13, 2022, Alvotech (the "Company") announced that Alvogen Lux Holdings S.à.r.l. and Aztiq Pharma Partners S.à.r.l. have each subscribed to newly issued shares of the Company for a price of \$10.00 per share. The announcement is furnished as Exhibit 99.1 to this Report on Form 6-K.

On July 13, 2022, the Company also announced the submission of a managers' transaction notification form to the Commission de Surveillance du Secteur Financier (CSSF) in Luxembourg. The announcement is furnished as Exhibit 99.2 to this Report on Form 6-K.

EXHIBIT INDEX

Exhibit No.	Description
99.1	Company announcement dated July 13, 2022.
99.2	Company announcement dated July 13, 2022.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ALVOTECH

By: /s/ Helga Tatjana Zharov

Name: Helga Tatjana Zharov Title: Deputy Chief Executive Officer

Date: July 13, 2022

Alvotech Société anonyme Registered office: 9, rue de Bitbourg, L-1273 Luxembourg R.C.S. Luxembourg: B258884

Aztiq and Alvogen subscribe to shares in Alvotech at listing price of \$10 per share

Alvogen Lux Holdings S.à r.l. ("Alvogen") and Aztiq Pharma Partners S.à r.l. ("Aztiq") have each subscribed to 2,500,000 newly issued shares of Alvotech (the "Company") for a price of \$10 per share. The 5,000,000 shares were issued pursuant to the terms of settlement agreements between the Company and each of Alvogen and Aztiq, executed on 12 July 2022, in respect of shareholder loans aggregating \$50,000,000, extended in February and March 2022. Under the terms of the settlement agreements, Alvogen and Aztiq agreed to receive Company shares in lieu of cash as repayment for the shareholder loans.

Consequently, the board of directors of the Company has on 12 July 2022 resolved to increase the Company's share capital by an amount of fifty million US dollars (\$50,000,000) through the issuance of five million (5,000,000) ordinary shares of the Company.

As a consequence, the number of ordinary shares issued by the Company has increased from 270,721,672 to 275,721,672, and the number of outstanding shares, issued by the Company, has increased from 243,649,505 to 248,649,505.

For further information:

Alvotech, Investor Relations Benedikt Stefansson benedikt.stefansson[at]alvotech.com

DISCLAIMER

This announcement is released by the Company and contains information that qualified or may have qualified as inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR). This announcement is made for the purposes of MAR and pursuant to Article 2 of Commission Implementing Regulation (EU) 2016/1055.

Transactions of managers and closely associated persons

Attached is an announcement on transactions of managers and closely associated persons.



Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them (HOS-2 form)

Filing reference	1255
Submitted at	2022-07-12 22:53

1. Details of the person discharging managerial responsibilities/person closely associated

Name ¹	Robert Wessman
	on behalf of Aztiq Pharma Partners S.à r.l.

2. Reason for the notification

Position/status ²	Aztiq Pharma Partners S.à r.l. is a person closely associated with Robert Wessman, a member of the Board of Directors
Initial notification/Amendment ³	Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name ⁴	Alvotech
LEI ⁵	222100DCZBOWV5DZ8372

4. Details of the transaction(s): section to be repeated for ¹ each type of instrument; ² each type of transaction; ³ each date; and ⁴ each place where transactions have been conducted:

Description of the financial instrument, type of instrument ⁶	Shares	
Identification code ⁷	LU2458332611	
Nature of the transaction ⁸	Acquisition	
	Subscription	
Price(s) and volume(s) ⁹	Price(s)	Volume(s)
	10 USD	2,500,000 (units)
Aggregated information Aggregated volume ¹⁰	2,500,000 (units)	
Price ¹¹	10 USD	
Date of the transaction ¹²	2022-07-12	
Place of transaction ¹³	- XOFF	

Notes

1 For natural persons: the first name and the last name(s). For legal persons: full name including legal form as provided for in the register where it is incorporated, if applicable.

² For persons discharging managerial responsibilities: the position occupied within the issuer, emission allowances market participant/auction platform/auctioneer/auction monitor should be indicated, e.g. CEO, CFO. For persons closely accociated:

- An indication that the notification concerns a person closely associated with a person discharging managerial responsibilities;
- Name and position of the relevant person discharging managerial responsibilities.

³ Indication that this is an initial notification or an amendment to prior notifications. In case of amendment, explain the error that this notification is amending.

⁴ Full name of the entity.

⁵ Legal Entity Identifier code in accordance with ISO 17442 LEI code.

⁶ Indication as to the nature of the instrument:

- A share, a debt instrument, a derivative or a financial instrument linked to a share or a debt instrument;
- An emission allowance, an auction product based on an emission allowance or a derivative relating to an emission allowance.

⁷ Instrument identification code as defined under Commission Delegated Regulation supplementing Regulation (EU) No 600/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the reporting of transactions to competent authorities adopted under Article 26 of Regulation (EU) No 600/2014.

⁸ Description of the transaction type using, where applicable, the type of transaction identified in Article 10 of the Commission Delegated Regulation (EU) 2016/522 adopted under Article 19(14) of Regulation (EU) No 596/2014 or a specific example set out in Article 19(7) of Regulation (EU) No 596/2014. Pursuant to Article 19(6)(e) of Regulation (EU) No 596/2014, it shall be indicated whether the transaction is linked to the exercise of a share option programme.

⁹ Where more than one transaction of the same nature (purchases, sales, lendings, borrows, ...) on the same financial instrument or emission allowance are executed on the same day and on the same place of transaction, prices and volumes of these transactions shall be reported in this field, in a two columns form as presented above, inserting as many lines as needed. Using the data standards for price and quantity, including where applicable the price currency and the quantity currency, as defined under Commission Delegated Regulation supplementing Regulation (EU) No 600/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the reporting of transactions to competent authorities adopted under Article 26 of Regulation (EU) No 600/2014.

¹⁰ The volumes of multiple transactions are aggregated when these transactions:

- Relate to the same financial instrument or emission allowance;
- Are of the same nature;
- Are executed on the same day;
- And are executed on the same place of transaction.

Using the data standard for quantity, including where applicable the quantity currency, as defined under Commission Delegated Regulation supplementing Regulation (EU) No 600/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the reporting of transactions to competent authorities adopted under Article 26 of Regulation (EU) No 600/2014.

11 Price information.

- In case of a single transaction, the price of the single transaction;
- In case the volumes of multiple transactions are aggregated: the weighted average price of the aggregated transactions.

Using the data standard for price, including where applicable the price currency, as defined under Commission Delegated Regulation supplementing Regulation (EU) No 600/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the reporting of transactions to competent authorities adopted under Article 26 of Regulation (EU) No 600/2014.

¹² Date of the particular day of execution of the notified transaction. Using the ISO 8601 date format: YYYY-MM-DD; UTC time.

¹³ Name and code to identify the MiFID trading venue, the systematic internaliser or the organised trading platform outside of the Union where the transaction was executed as defined under Commission Delegated Regulation supplementing Regulation (EU) No 600/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the reporting of transactions to competent authorities adopted under Article 26 of Regulation (EU) No 600/2014, or if the transaction was not executed on any of the above mentioned venues, please mention "outside a trading venue".